PROCEPT BioRobotics annual free cash flow
2020
2021
2022
2023
2024
2025
PROCEPT BioRobotics Free Cash Flow (FCF) History (PRCT)
PROCEPT BioRobotics reported −$58.3M in free cash flow for fiscal 2025, an increase of $45.3M from the previous fiscal year, with a free cash flow margin of −18.94%.
View full PROCEPT BioRobotics company overviewPROCEPT BioRobotics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$58.3M | $45.3M | — | −18.94% |
| 2024 | 2024-12-31 | −$103.6M | $29.6M | — | −46.16% |
| 2023 | 2023-12-31 | −$133.2M | −$50.2M | — | −97.81% |
| 2022 | 2022-12-31 | −$83.0M | −$25.1M | — | −110.69% |
| 2021 | 2021-12-31 | −$57.9M | −$9.3M | — | −168.03% |
| 2020 | 2020-12-31 | −$48.6M | — | — | −629.47% |
PROCEPT BioRobotics quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$22.2M | −$4.4M | — | −23.50% |
| Q1 2026 | 2026-03-31 | −$41.0M | −$22.2M | — | −49.37% |
| Q4 2025 | 2025-12-31 | −$12.2M | $21.4M | — | −15.94% |
| Q3 2025 | 2025-09-30 | −$9.5M | $9.5M | — | −11.40% |
| Q2 2025 | 2025-06-30 | −$17.8M | −$1.1M | — | −22.54% |
| Q1 2025 | 2025-03-31 | −$18.8M | $15.4M | — | −27.21% |
| Q4 2024 | 2024-12-31 | −$33.6M | −$57,000 | — | −49.19% |
| Q3 2024 | 2024-09-30 | −$19.0M | $5.7M | — | −32.63% |
| Q2 2024 | 2024-06-30 | −$16.8M | $16.9M | — | −31.45% |
| Q1 2024 | 2024-03-31 | −$34.2M | $7.0M | — | −76.86% |
| Q4 2023 | 2023-12-31 | −$33.5M | −$7.5M | — | −76.89% |
| Q3 2023 | 2023-09-30 | −$24.7M | −$3.4M | — | −70.43% |
| Q2 2023 | 2023-06-30 | −$33.7M | −$16.4M | — | −101.83% |
| Q1 2023 | 2023-03-31 | −$41.3M | −$23.0M | — | −169.10% |
| Q4 2022 | 2022-12-31 | −$26.0M | −$9.2M | — | −109.52% |
| Q3 2022 | 2022-09-30 | −$21.4M | −$8.5M | — | −104.99% |
| Q2 2022 | 2022-06-30 | −$17.3M | −$4.3M | — | −103.91% |
| Q1 2022 | 2022-03-31 | −$18.3M | −$3.0M | — | −128.80% |
| Q4 2021 | 2021-12-31 | −$16.8M | — | — | −165.81% |
| Q3 2021 | 2021-09-30 | −$12.9M | — | — | −148.38% |
| Q2 2021 | 2021-06-30 | −$13.0M | — | — | −153.60% |
| Q1 2021 | 2021-03-31 | −$15.2M | — | — | −211.86% |
PROCEPT BioRobotics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$48.6M to −$58.3M, a net decrease of $9.8M. PROCEPT BioRobotics's latest reported quarter, Q2 2026, generated −$22.2M in free cash flow, a decrease of $4.4M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review PROCEPT BioRobotics filings at SEC.gov ↗